Skip to content
Search

Latest Stories

Second virus wave could cause up to 120,000 deaths in hospitals alone, says study

A SECOND coronavirus wave in Britain this winter could see 120,000 deaths in hospitals alone in a "reasonable worst-case scenario", scientists warned on Tuesday (14).

The Academy of Medical Sciences report, commissioned by the government's chief scientific adviser Patrick Vallance, urged immediate action to mitigate a second wave.


With hospitals also battling seasonal flu cases, a second wave could eclipse the current outbreak resulting in up to 120,000 deaths between September and June next year.

The modelling does not include deaths in care homes or the wider community, and assumes no government action to prevent a fresh surge in cases.

Britain has seen almost 45,000 deaths so far in the first wave -- the highest toll in Europe and third only to the United States and Brazil.

The latest predictions are based on an assumption that the R rate -- which measures how many people an infected person is expected to infect -- rises to 1.7 from September.

The scientists also modelled for an lower increased R rate of 1.5, which would lead to 74,800 deaths.

The R rate is currently between 0.7 to 0.9 across the whole country, according to the latest government figure published last Friday.

Stephen Holgate, who led the study, said the 120,000 figure was "not a prediction but it is a possibility".

"The modelling suggests that deaths could be higher with a new wave of Covid-19 this winter, but the risk of this happening could be reduced if we take action immediately."

'Intense preparation'

The group of 37 scientists involved in the report said the government needed to prepare immediately because of the "serious risk" to health of a potential surge in cases.

A winter outbreak could be worse due to people spending more time indoors, where the virus can spread more easily, added Azra Ghani, from Imperial College London.

The report calls for "intense preparation" this month and next to prevent the country's state-run National Health Service (NHS) from being overwhelmed.

That includes work to minimise community transmission, a public information campaign and ensuring enough protective equipment for frontline medical and social care staff.

The government's test, trace and isolate programme also needed to be scaled up, along with surveillance and ensuring at risk individuals, health and care workers get flu jabs.

More For You

Prada 2026 sandals

Prada acknowledges Indian influence behind its Spring Summer 2026 men’s footwear

Instagram/prada/iStock

Prada finally acknowledges Kolhapuri chappals inspired 2026 sandals after Indian backlash over Milan show

Quick highlights:

• Prada confirms Indian roots behind 2026 ‘leather sandals’ after controversy
• Indian artisans and officials accused the brand of cultural appropriation
• The footwear resembles traditional Kolhapuri chappals with GI status
• Prada says designs are still in development and open to dialogue with India

Keep ReadingShow less
Anna Wintour

Wintour’s style of leadership earned her the nickname “Nuclear Wintour”

Getty Images

Anna Wintour steps down as editor of US Vogue after 37 years

Key points

  • Anna Wintour steps down as editor of US Vogue after 37 years
  • She will remain Vogue’s global editorial director and hold senior roles at Condé Nast
  • Wintour transformed US Vogue into a global fashion authority
  • The 75-year-old has received numerous honours, including the Presidential Medal of Freedom

End of an era at US Vogue

Anna Wintour has stepped down as the editor of US Vogue, bringing to a close a 37-year tenure that redefined the publication and saw her become one of the most influential figures in global fashion.

The announcement was made on Thursday (26 June) during a staff meeting in New York. Wintour, 75, will no longer oversee the day-to-day editorial operations of Vogue’s US edition. However, she will continue to serve as Vogue’s global editorial director and Condé Nast’s chief content officer, maintaining senior leadership roles across the company.

Keep ReadingShow less
Nadiya Hussain

She also reassured her followers that “exciting” new projects are on the way

Getty Images

“I won’t always be grateful” says Nadiya Hussain after BBC axes her cookery show

Key points

  • Nadiya Hussain confirms BBC will not renew her cookery series
  • Bake Off winner challenges expectations to remain “grateful”
  • She says hard work and talent, not luck, brought her success
  • Celebrities, including Annie Lennox and Fearne Cotton, show support

BBC ends decade-long collaboration with Bake Off star

Nadiya Hussain has spoken out after the BBC decided not to commission another cookery programme with her. The popular TV chef, who won The Great British Bake Off in 2015, shared her views on social media, stating that she “won’t always be grateful” and should not be expected to remain silent about career setbacks.

The decision ends a nearly 10-year working relationship between the broadcaster and Hussain, who has hosted several well-received cookery shows under the BBC banner. In her latest Instagram video, she addressed the public’s reaction and emphasised her right to expect more from her career.

Keep ReadingShow less
weight loss injections UK

The importance of vigilance as demand for these weight loss and diabetes drugs continues to grow

iStock

Hundreds report pancreas issues linked to weight loss injections as UK launches safety study

Key points

  • Almost 400 reports of acute pancreatitis linked to weight loss and diabetes jabs have been filed in the UK
  • Most cases involve popular GLP-1 drugs including Ozempic, Wegovy, and Mounjaro
  • Health officials are investigating possible genetic causes behind the side-effects
  • Patients hospitalised with pancreatitis encouraged to report symptoms via MHRA’s Yellow Card scheme
  • Adverse drug reactions cost the NHS an estimated £2.2bn annually

Health watchdog investigates spike in serious side-effects from GLP-1 drugs

UK health authorities have launched a study into the side effects of popular weight loss and diabetes drugs following a spike in reported cases of acute pancreatitis. Nearly 400 reports have been received via the Medicines and Healthcare products Regulatory Agency’s (MHRA) Yellow Card scheme, which monitors side effects and adverse reactions related to medicines and medical devices.

The medicines involved are GLP-1 receptor agonists – including semaglutide (marketed as Ozempic and Wegovy), liraglutide, and tirzepatide (branded as Mounjaro). The Yellow Card data shows that 181 of the cases involved tirzepatide alone.

Keep ReadingShow less
M&S launches strawberries

M&S’s latest offering taps into both tradition and innovation

The Wire

M&S launches strawberries and cream sandwich ahead of Wimbledon

Summary

  • M&S unveils limited edition strawberries and cream sandwich for £2.80
  • Inspired by Japanese 'sweet sandos', it features Red Diamond strawberries and whipped cream cheese
  • Available in stores now, found in the savoury sandwich aisle
  • Launch coincides with Wimbledon and British strawberry season
  • Wimbledon increases strawberries and cream price for first time in 15 years

New summer sandwich from M&S

Marks & Spencer has launched a limited edition M&S strawberry sandwich, combining classic British summer flavours with a Japanese twist. Priced at £2.80, the strawberries and cream sandwich is available in M&S stores now.

The dessert-style sandwich features M&S’s exclusive Red Diamond strawberries, whipped cream cheese, and sweetened bread. Despite its sweet contents, the product is found in the savoury sandwich section of M&S Food halls.

Keep ReadingShow less